Apixaban

BreastfeedingPediatric
  • TRADE NAME: Eliquis (Bristol-Myers Squibb)
  • INDICATIONS: Reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
  • CLASS: Anticoagulant, Direct factor Xa inhibitor
  • HALF-LIFE: 5–12 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Carbamazepine, Darunavir, Phenytoin, Rifampin, St John's Wort, Tipranavir, Voriconazole

PREGNANCY CATEGORY: B

Contra-indicated in patients with active pathological bleeding.

DISCONTINUING ELIQUIS IN PATIENTS WITHOUT ADEQUATE CONTINUOUS ANTICOAGULATION INCREASES RISK OF STROKE

See full prescribing information for complete boxed warning.

Our database has 24 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
OCULAR.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of apixaban in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/05/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top